A Phase 4 interventional study of Pletal in Raynaud's Disease, sponsored by Otsuka America Pharmaceutical. Completed at 19 sites in United States. Open to participants aged 5 Years to 16 Years. Per ClinicalTrials.gov, last updated 2005-07-19.
Sponsored by Otsuka America Pharmaceutical (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.
Among the 33 studies in Raynaud Disease with a site in United States, this one is the 11th largest by enrollment, is one of 3 that started in 2001, is one of 5 in phase 4, and was the 1st registered.
81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.
Browse Raynaud Disease studies →2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Robyn T. Domsic, MD, MPH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 5 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 9 · Phase 4 5
First in 2001; this study’s year is marked. 3 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 30 across 67 interventional studies indexed under Raynaud Disease.
Median enrollment 34 across the 33 interventional studies. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka America Pharmaceutical, one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka America Pharmaceutical is the lead sponsor of 10 studies on the registry; none are open to participants now.
Otsuka Holdings Co., Ltd. has 2 studies filed under Raynaud Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Raynaud Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed connective tissue disease. When children with secondary Raynaud's are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of secondary Raynaud's episodes in juvenile patients.
Inclusion Criteria
The record gives a start of Oct 2001 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol
Otsuka America Pharmaceutical →